211 related articles for article (PubMed ID: 16508724)
21. Molecular pathology of endometrial carcinoma: transcriptional signature in endometrioid tumors.
Abal M; Planaguma J; Gil-Moreno A; Monge M; Gonzalez M; Baro T; Garcia A; Castellvi J; Ramon Y Cajal S; Xercavins J; Alameda F; Reventos J
Histol Histopathol; 2006 Feb; 21(2):197-204. PubMed ID: 16329044
[TBL] [Abstract][Full Text] [Related]
22. cDNA microarray analysis and immunohistochemistry reveal a distinct molecular phenotype in serous endometrial cancer compared to endometrioid endometrial cancer.
Chen Y; Yao Y; Zhang L; Li X; Wang Y; Zhao L; Wang J; Wang G; Shen D; Wei L; Zhao J
Exp Mol Pathol; 2011 Aug; 91(1):373-84. PubMed ID: 21540026
[TBL] [Abstract][Full Text] [Related]
23. Endometrial giant cell carcinoma: a case series and review of the spectrum of endometrial neoplasms containing giant cells.
Mulligan AM; Plotkin A; Rouzbahman M; Soslow RA; Gilks CB; Clarke BA
Am J Surg Pathol; 2010 Aug; 34(8):1132-8. PubMed ID: 20588176
[TBL] [Abstract][Full Text] [Related]
24. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of tyrosine threonine kinase inhibits tumor growth via G2/M arrest in human endometrioid endometrial adenocarcinoma.
Zhang J; Jiang Y; Zhao Y; Wang W; Xie Y; Wang H; Yang Y
Tumour Biol; 2017 Jul; 39(7):1010428317712444. PubMed ID: 28718377
[TBL] [Abstract][Full Text] [Related]
26. The expression of the miRNA-200 family in endometrial endometrioid carcinoma.
Lee JW; Park YA; Choi JJ; Lee YY; Kim CJ; Choi C; Kim TJ; Lee NW; Kim BG; Bae DS
Gynecol Oncol; 2011 Jan; 120(1):56-62. PubMed ID: 21035172
[TBL] [Abstract][Full Text] [Related]
27. High-grade endometrial carcinomas - strategies for typing.
Soslow RA
Histopathology; 2013 Jan; 62(1):89-110. PubMed ID: 23240672
[TBL] [Abstract][Full Text] [Related]
28. Molecular Genetics of Endometrial Carcinoma.
Bell DW; Ellenson LH
Annu Rev Pathol; 2019 Jan; 14():339-367. PubMed ID: 30332563
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance and clinical importance of estrogen receptor alpha and beta in human endometrioid adenocarcinomas.
Mylonas I
Oncol Rep; 2010 Aug; 24(2):385-93. PubMed ID: 20596625
[TBL] [Abstract][Full Text] [Related]
30. LAT1 is a putative therapeutic target in endometrioid endometrial carcinoma.
Marshall AD; van Geldermalsen M; Otte NJ; Anderson LA; Lum T; Vellozzi MA; Zhang BK; Thoeng A; Wang Q; Rasko JE; Holst J
Int J Cancer; 2016 Dec; 139(11):2529-39. PubMed ID: 27486861
[TBL] [Abstract][Full Text] [Related]
31. [Cancer of the endometrium].
Leblanc E; Narducci F
Rev Med Suisse; 2007 Nov; 3(133):2616-8, 2620-2. PubMed ID: 18078193
[No Abstract] [Full Text] [Related]
32. P16INK4a expression in undifferentiated carcinoma of the uterus does not exclude its endometrial origin.
Saad RS; Mashhour M; Noftech-Mozes S; Ismiil N; Dubé V; Ghorab Z; Faragalla H; Khalifa MA
Int J Gynecol Pathol; 2012 Jan; 31(1):57-65. PubMed ID: 22123724
[TBL] [Abstract][Full Text] [Related]
33. The oncological safety of hysteroscopy in the diagnosis of early-stage endometrial cancer: An Israel gynecologic oncology group study.
Namazov A; Gemer O; Helpman L; Hag-Yahia N; Eitan R; Raban O; Vaknin Z; Leytes S; Lavie O; Amit A; Levy T; Volodarsky M; Ben Shachar I; Atlas I; Bruchim I; Ben-Arie A
Eur J Obstet Gynecol Reprod Biol; 2019 Dec; 243():120-124. PubMed ID: 31689674
[TBL] [Abstract][Full Text] [Related]
34. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
[TBL] [Abstract][Full Text] [Related]
35. The Prediction of Recurrence in Low-Risk Endometrial Cancer: Is It Time for a Paradigm Shift in Adjuvant Therapy?
Laban M; El-Swaify ST; Ali SH; Refaat MA; Sabbour M; Farrag N; Hassanin AS
Reprod Sci; 2022 Apr; 29(4):1068-1085. PubMed ID: 33856667
[TBL] [Abstract][Full Text] [Related]
36. Endometrial endometrioid carcinoma: a glimpse at the natural course.
Levy T; Golan A; Menczer J
Am J Obstet Gynecol; 2006 Aug; 195(2):454-7. PubMed ID: 16626613
[TBL] [Abstract][Full Text] [Related]
37. Impact of Adjuvant Modalities on Survival in Patients with Advanced Stage Endometrial Carcinoma: A Retrospective Analysis from a Tertiary Medical Center.
Tai YJ; Hsu HC; Chiang YC; Chen YL; Chen CA; Cheng WF
Int J Environ Res Public Health; 2019 Jul; 16(14):. PubMed ID: 31323767
[TBL] [Abstract][Full Text] [Related]
38. Actual trends in screening, diagnosis and prognosis of endometrial cancer.
Chiovschi S; Moldovan M; Cioată IT
Clin Exp Obstet Gynecol; 2003; 30(4):178-82. PubMed ID: 14664404
[TBL] [Abstract][Full Text] [Related]
39. Role of Immunohistochemistry to Distinguish Grade 3 Endometrioid Carcinoma and Uterine Serous Carcinoma.
Zaidi A; Gupta P; Gupta N; Rajwanshi A; Rai B; Gainder S
Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):42-48. PubMed ID: 31815745
[TBL] [Abstract][Full Text] [Related]
40. SOX17, β-catenin and CyclinD1 expression in the endometrioid adenocarcinoma and influence of 5-AZA on expression.
Liao YM; Song Y; Li YK; Du JH; Zhou Y
Cancer Gene Ther; 2020 Apr; 27(3-4):256-263. PubMed ID: 31543512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
